- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04415086
Treatment of Patients With COVID-19 With Convalescent Plasma (COOPCOVID-19)
May 17, 2022 updated by: University of Sao Paulo General Hospital
Treatment of Patients With COVID-19 With Convalescent Plasma Transfusion: a Multicenter, Open-labeled, Randomized and Controlled Study
The COVID-19 pandemic has been spreading continuously, and in Brazil, until May 31, 2020, there have been more than 450.000 cases with more than 28.000 deaths, with daily increases.
The present study proposes to evaluate the efficacy and safety of convalescent plasma in treatment of severe cases of COVID-19 in a multicenter, randomized, open-label and controlled study
Study Overview
Detailed Description
Eligible patients will be randomized 1:1:1 into 3 treatment groups: A- standard (control); B- standard and convalescent plasma in a volume of 200ml (150-300ml); C- standard and convalescent plasma in a volume of 400ml (300-600ml).
The Bayesian multi-arm and multi-stage model will be used, which will allow an interim analysis after the inclusion of 30 patients, with repeated interim analyses for every 30 additional patients.
With this, we expect to define not only the efficacy of convalescent plasma, but also the volume of plasma needed if efficacy is proven.
The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment.
The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
Study Type
Interventional
Enrollment (Actual)
129
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
SP
-
São Paulo, SP, Brazil, 01403-002
- University of Sao Paulo - General Hospítal
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age = or > than 18 years; .
- Laboratory-proven COVID-19 infection by RT-PCR in any clinical sample . Time since symptom onset less than 10 days at the time of screening; - . Presence of COVID-19 pneumonia, with a typical, indeterminate or atypical compatible image in a chest tomography exam (see definition below) -
- Presence of one of the following criteria:
- Need for> 3L of O2 in the catheter / mask or> 25% in the Venturi mask to maintain O2 saturation> 92% B presence of respiratory distress syndrome with PaO2 / FiO2 <300mmHg If intubated, within 48 hours of orotracheal intubation
- Absence of a history of serious adverse reactions to transfusion, for example, anaphylaxis; - .Participation approval by the research clinician
Exclusion Criteria:
- Already enrolled in another clinical trial evaluating antiviral or immunobiological therapy for the treatment of COVID-19.
- IgA deficiency
- Presence of a clinical condition that does not allow infusion of 400 ml of volume at clinical discretion
- Pregnancy or breastfeeding
- Receipt of immunoglobulin in the last 30 days
- Presence of significant risk of death within the next 48 hours at clinical discretion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Group A
Participants will receive the standard of care treatment
|
The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment.
The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
|
Active Comparator: Group B
Participants will receive the standard treatment and convalescent plasma in a volume of 200ml (150-300ml)
|
The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment.
The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
|
Active Comparator: Group C
Participants will receive the standard treatment and convalescent plasma in a volume of 400ml (300-600ml)
|
The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment.
The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time elapsed until clinical improvement or hospital discharge
Time Frame: Follow up until 28 days after transfusion
|
clinical improvement is defined as the time from the randomization date until the decline of 2 categories on the ordinal scale of 10 categories or hospital discharge (whichever comes first)
|
Follow up until 28 days after transfusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
acute adverse events
Time Frame: Up to 12 hours after transfusion
|
incidence of acute adverse events possibly or definitively realted to convalescent plasma transfusion
|
Up to 12 hours after transfusion
|
Clinical Status
Time Frame: "Day 7", "Day 14" and "Day 28"
|
Evaluation according to an ordinal scale of 10 categories
|
"Day 7", "Day 14" and "Day 28"
|
Duration of clinical events
Time Frame: Up to 28 days
|
Duration of mechanical ventilation, length of hospital stay in survivors up to 28 days and time from the beginning of treatment to death
|
Up to 28 days
|
SARS-CoV-2 in nasopharyngeal swab
Time Frame: Days 0, 1, 3, 7, 14 and 28 after transfusion and control groups
|
Detection of SARS-CoV-2 in nasopharyngeal swab
|
Days 0, 1, 3, 7, 14 and 28 after transfusion and control groups
|
IgG, IgM and IgA titers for SARS-CoV-2
Time Frame: Days 0, 1, 3, 5, 7, 14 and 28 after transfusion and control groups
|
Specific IgG, IgM and IgA titers for SARS-CoV-2
|
Days 0, 1, 3, 5, 7, 14 and 28 after transfusion and control groups
|
Neutralizing antibodies
Time Frame: 0,1,7 14 and 28 days after transfusion and control groups
|
Titers of neutralizing antibodies
|
0,1,7 14 and 28 days after transfusion and control groups
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Esper G Kallás, PhD, MD, University of Sao Paulo General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2020
Primary Completion (Actual)
February 15, 2022
Study Completion (Actual)
February 15, 2022
Study Registration Dates
First Submitted
June 1, 2020
First Submitted That Met QC Criteria
June 2, 2020
First Posted (Actual)
June 4, 2020
Study Record Updates
Last Update Posted (Actual)
May 19, 2022
Last Update Submitted That Met QC Criteria
May 17, 2022
Last Verified
October 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COOP-COVID-19-MCTIC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on convalescent plasma
-
Noah MerinJohns Hopkins UniversityTerminatedCovid-19 | Sars-CoV2United States
-
Gailen D. Marshall Jr., MD PhDUniversity of Mississippi Medical CenterCompleted
-
Federal Research Clinical Center of Federal Medical...Completed
-
Thomas BenfieldTerminatedCOVID | Corona Virus Infection | Viral PneumoniaDenmark
-
Lahore General HospitalUnknown
-
Max O'DonnellNew York Blood Center; Amazon.com, Inc.Completed
-
Henry Ford Health SystemCompletedCoronavirus Infection | COVID | CoronavirusUnited States
-
Universidad Peruana Cayetano HerediaCompleted
-
Ministry of Health and Population, EgyptCompletedCovid19 | Plasma | Convalescent Plasma | Immunoglobulins | EgyptEgypt